Giulio Draetta, The University of Texas MD Anderson Cancer Center, USA
Dr. Giulio Draetta

As a physician/scientist, Dr. Giulio Draetta spent nearly three decades in oncology research and drug discovery in both academia and industry. In 2011, he embraced the opportunity to lead to lead the MD Anderson Cancer Center Institute for Applied Cancer Science as well as his own research laboratory. This combination allows an opportunity for truly transformative research, combining best practices from both academia and industry with the goal of rapidly translating basic discoveries into patient therapies. The group is interested in finding new approaches for treating some of the most elusive and devastating tumors, including PDAC and glioblastoma multiforme. Though a biochemist with expertise in the cell cycle and development pathways by training, Dr. Draetta's group is now focusing on harnessing the power of various -omics analyses, and in particular the development of in vivo functional genomic screens, to inform on new therapeutic targets. The laboratory pursues new approaches to treat some of the most elusive and devastating tumors, including pancreatic ductal adenocarcinoma (PDAC), and glioblastoma multiform. They employ a variety of techniques, including harnessing the power of -omics analyses and conducting large-scale in vivo functional genomic screens to inform on new therapeutic targets. Their goal is to rapidly validate the clinical relevance of identified mechanisms and to translate our findings into clinical opportunities. We are particularly interested in studying the impact of deregulated tumor metabolism and epigenetics in treatment-resistant cancer cells.


« Go Back